Ivan Brian FXStreet Follow Following

Moderna (MRNA) underperformed on Tuesday as a global equity rout took hold following higher-than-expected US inflation. The move in Moderna was to be expected, but the underperformance versus the main indices is a bit perplexing. Moderna is cash rich and would not be associated with long-duration stocks. Therefore, it would not fall into the yield-sensitive group of many other Nasdaq names. It was a high-growth story, yes, but now it has matured and so too have its cash flows. The company has an enormous pile of cash, which it will partly use for buyback and perhaps dividends in the future.

However, it is news from Reuters this morning that is capturing my attention. According to the report, Moderna CEO Stephane Bancel has spoken with the Chinese government about supplying its Covid-19 vaccine to China. As of yet, no decision has been made.

"We are open, [and] we have the capacity," CEO Bancel said. He was speaking in Tokyo where he also said Moderna is open to building manufacturing capacity to make mRNA products. Moderna has reportedly filed a lawsuit against Pfizer (PFE) and BioNTech (BNTX) for patent infringement involving cold vaccine development in the US. 

Moderna says in its lawsuit that Pfizer and BioNTech's COVID-19 vaccine Comirnaty infringes on patents that Moderna filed between 2010 and 2016 covering mRNA technology.

The news over the lawsuit is too far out to generate any meaningful catalyst in my view. This could drag on for some time. However, any announcement of a deal with China would be a huge positive. It sounds like it may be a long shot, but with the world's largest population it would represent a massive opportunity for Moderna. As it stands, the company is well placed with cash of nearly $11 billion and little debt. 

This is for now a short-term opportunity to perhaps bottom fish after Tuesday's sell-off and see if this story gets more legs to it. Moderna is perched precariously on support at $125, and a break will target then $100. This $120 to $125 zone has been held several times going back to March 2021, so it is key support.

Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.

If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.

FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.

The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.

GBP/USD managed to stage a rebound from the multi-decade low it touched at 1.1350 earlier in the day and rose above 1.1400. The renewed dollar weakness following the UoM Consumer Sentiment Survey fuels the pair's recovery ahead of the weekend.

EUR/USD has gathered recovery momentum and climbed above parity during the American trading hours on Friday. The greenback stays on the backfoot amid week-end flows and the soft inflation components of the UoM survey, allowing the pair to push higher.

Gold gained traction and turned positive on the day above $1,670 in the American session on Friday. The UOM's Consumer Sentiment Survey showed declines in one-year and five-year inflation expectations, causing US yields to push lower and lifting XAU/USD.

Cardano price continues to shed gains after a sweep of the $0.505 resistance level. Continued selling pressure could see ADA drop to the $0.435 support level.

FedEx (FDX) stole the headlines on Thursday with its poor quarterly earnings release. What seeped into the sell-off of similar stocks though was the parcel delivery company's withdrawing of full-year guidance. 

Note: All information on this page is subject to change. The use of this website constitutes acceptance of our user agreement. Please read our privacy policy and legal disclaimer.

Trading foreign exchange on margin carries a high level of risk and may not be suitable for all investors. The high degree of leverage can work against you as well as for you. Before deciding to trade foreign exchange you should carefully consider your investment objectives, level of experience and risk appetite. The possibility exists that you could sustain a loss of some or all of your initial investment and therefore you should not invest money that you cannot afford to lose. You should be aware of all the risks associated with foreign exchange trading and seek advice from an independent financial advisor if you have any doubts.

Opinions expressed at FXStreet are those of the individual authors and do not necessarily represent the opinion of FXStreet or its management. FXStreet has not verified the accuracy or basis-in-fact of any claim or statement made by any independent author: errors and Omissions may occur.Any opinions, news, research, analyses, prices or other information contained on this website, by FXStreet, its employees, partners or contributors, is provided as general market commentary and does not constitute investment advice. FXStreet will not accept liability for any loss or damage, including without limitation to, any loss of profit, which may arise directly or indirectly from use of or reliance on such information.